High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry.
Claudia Diniz Lopes MarquesAdriana Maria KakehasiMarcelo Medeiros PinheiroLicia Maria Henrique MotaCleandro Pires AlbuquerqueCarolina Rocha SilvaGabriela Porfirio Jardim SantosEdgard Torres Reis-NetoPedro MatosGuilherme DevideAndrea DantasRina Dalva GiorgiAdriana de Oliveira MarinhoLilian David Azevedo ValadaresAna Karla G MeloFrancinne Machado RibeiroGilda Aparecida FerreiraFlavia Patricia de Sena SantosSandra Lucia Euzebio RibeiroNicole Pamplona Bueno AndradeMichel Alexandre YazbekViviane Angelina de SouzaEduardo S PaivaValderilio Feijo AzevedoAna Beatriz Santos Bacchiega de FreitasJosé Roberto ProvenzaRicardo Acayaba de ToledoSheilla FontenelleSueli CarneiroRicardo XavierGecilmara Cristina Salviato PileggiAna Paula Monteiro Gomides ReisPublished in: RMD open (2021)
Age >50 years and immunosuppression with GC and cyclophosphamide were associated with unfavourable outcomes of COVID-19. Treatment with TNFi may have been protective, perhaps leading to the COVID-19 inflammatory process.